Pfizer and clinical research site organisation Headlands Research have entered a collaboration to launch new research sites in regions with vastly diverse populations to boost diversity in clinical trials.
This partnership is said to further progress the mission of Headlands to enhance diverse trial participation.
Under the collaboration, the first trial site will be opened at a new facility of Headlands in Brownsville, Texas, US.
This alliance is a multi-year commitment to launch several diversity-focused sites.
Headlands Research CEO and founder Mark Blumling said: “Diversity is a key pillar of our commitment to ensure clinical trials represent broader populations.
“We are proud to partner with Pfizer as we take another meaningful step forward toward achieving this extremely important goal.”
Headlands’ network of sites focuses on large scale enrolment of varied and specialty patients while offering data.
Principal investigators of the organisation are industry experts in their fields with experience in various indications.
Leveraging the expert recruitment approaches and access to the diverse patient population through its site databases and physician collaboration, Headlands has concluded over 5000 trials.
In May last year, Headlands acquired Summit Research Network in Portland, Oregon, US.
Furthermore, the entity also unveiled its fourth Horizons site in Scottsdale, extending its worldwide network to 15 trial sites.
In March this year, Pfizer and UC Davis Health in the US announced plans for analysing a Covid-19 booster vaccine in two trials in healthy adult subjects.
At present, UC Davis is enrolling participants who have received two doses of the Pfizer’s Covid-19 vaccine at the Sacramento clinic.